Previous 10 | Next 10 |
Funds available expected to be sufficient for Genenta to continue to operate into the first quarter of 2025 Net exchange rate gain of €2.3 million Tax credit of €6.4 million MILAN, Italy and NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. ...
MILAN, Italy and NEW YORK, April 03, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, today announced that th...
The U.S. Food and Drug Administration (FDA) granted orphan drug designation (ODD) to Genenta Science's ( NASDAQ: GNTA ) to Temferon to treat glioblastoma multiforme (GBM), a type of brain cancer. Temferon is a cell therapy aimed at reprograming the tumor microenvironment by deliv...
MILAN and NEW YORK, March 02, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, today announced that the U.S. ...
Genenta (NASDAQ: GNTA) is a clinical-stage biotechnology company engaged in the development of a proprietary hematopoietic stem cell gene therapy for the treatment of a variety of solid tumor cancers. Temferon(TM) is based on ex-vivo gene transfer into autologous Tie2+ hematopoietic stem/progeni...
Genenta Science ( NASDAQ: GNTA ) signed an agreement with AGC Biologics to manufacture cell therapy lentivirus-based product for Genenta's ongoing clinical programs. Genenta had an existing manufacturing services agreement (MSA) with Molecular Medicine's facility in Milan, which was a...
MILAN, N.Y., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company engaged in the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, has entered into a development and manufacturing service agreement (MSA) with AGC ...
• Signs of intra-tumor pro-inflammatory state in patients • Temferon™ induced immune system reset in preclinical studies • Macrophage and T cell profiles in patients’ tumor microenvironment echo preclinical findings MILAN, Italy and NEW YORK, Nov. ...
Genenta Science press release ( NASDAQ: GNTA ): 1H GAAP EPS of €0.27 beats by €0.42 . Cash and cash equivalents of €34.7 million as of June 30, 2022. €1.8 million unrealized foreign exchange gain. For further details see: ...
Current dose escalation study data shows a median overall survival of 17 months Adding cohort to Phase 1/2a trial in GBM to assess additional conditioning regimen Cash and cash equivalents of €34.7 million as of June 30, 2022, providing a cash runway until the end of 2024...
News, Short Squeeze, Breakout and More Instantly...
Genenta Science S.p.A. Company Name:
GNTA Stock Symbol:
NASDAQ Market:
MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage immuno-oncology company developing...
MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that ...
A look at the top 10 most actives in the United States Chicken Soup for the Soul Entertainment Inc. (CSSE) rose 179.3% to $0.4253 on volume of 213,352,319 shares Tesla Inc. (TSLA) rose 12.1% to $162.13 on volume of 179,967,315 shares PROSHARES TRUST (SQQQ) fell 0.8% to $11.81 on volume of...